![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/9/94/Coronavirus._SARS-CoV-2.png/640px-Coronavirus._SARS-CoV-2.png&w=640&q=50)
ZF2001
Vaccine against COVID-19 / From Wikipedia, the free encyclopedia
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences.[1][2] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.[3][4]
![]() Logo | |
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Trade names | Zifivax |
Routes of administration | Intramuscular |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
DrugBank |
ZF2001 employs technology similar to other protein-based vaccines[5] in Phase III trials from Novavax, Vector Institute, and Medicago.[6]
ZF2001 was first approved for use in Uzbekistan and later China.[7][8] Production capacity is expected to be one billion doses a year in China[9] and 200 million in Uzbekistan.[10] By July, 100 million doses had been administered in China and Uzbekistan.[11]